Quantification of endocannabinoids in postmortem brain of schizophrenic subjects

Schizophrenia Research

Volumn 148, Issue 1-3, 2013, Pages 145-150

  Muguruza, Carolina ^a,b   Lehtonen, Marko ^c   Aaltonen, Niina ^c   Morentin, Benito ^d   Meana, J Javier ^a,b,e   Callado, Luis F ^a,b,e  

^a UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE SALUD MENTAL CIBERSAM   (Spain)

^c UNIVERSITY OF EASTERN FINLAND   (Finland)

^d Basque Institute of Legal Medicine   (Spain)

^e BIOCRUCES BIZKAIA HEALTH RESEARCH INSTITUTE   (Spain)

Author keywords

2 Arachidonoyl glycerol; Anandamide; Antipsychotic; Endocannabinoids; Human brain; Schizophrenia

Indexed keywords

2 ARACHIDONOYLGLYCEROL; ANANDAMIDE; CANNABINOID DERIVATIVE; DIHOMO GAMMA LINOLENOYLETHANOLAMINE; DOCOSAHEXAENOYLETHANOLAMINE; ENDOCANNABINOID; NEUROLEPTIC AGENT; OLEOYLETHANOLAMINE; PALMITOYLETHANOLAMINE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; AUTOPSY; BRAIN LEVEL; CEREBELLUM; CLINICAL ARTICLE; FEMALE; HIPPOCAMPUS; HUMAN; HUMAN TISSUE; MALE; MULTICENTER STUDY; PATHOPHYSIOLOGY; PREFRONTAL CORTEX; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SCHIZOPHRENIA;

2-ARACHIDONOYL GLYCEROL; ANANDAMIDE; ANTIPSYCHOTIC; ENDOCANNABINOIDS; HUMAN BRAIN; SCHIZOPHRENIA;

ADULT; ANALYSIS OF VARIANCE; ANTIPSYCHOTIC AGENTS; BRAIN; CASE-CONTROL STUDIES; CHROMATOGRAPHY, LIQUID; ENDOCANNABINOIDS; FEMALE; HUMANS; MALE; MIDDLE AGED; POSTMORTEM CHANGES; SCHIZOPHRENIA; TANDEM MASS SPECTROMETRY;

EID: 84881021978     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2013.06.013     Document Type: Article

References (30)

1. Alexander S.P.H., Kendall D.A. The life cycle of the endocannabinoids: formation and inactivation. Behavioral Neurobiology of the Endocannabinoid System 2009, 3-35. Springer. S.P.H. Alexander, D.A. Kendall (Eds.).
2. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders 1994, American Psychiatric Press, Washington, DC. 4th ed.
3. Andersson M., Terasmaa A., Fuxe K., Strömberg I. Subchronic haloperidol increases CB1 receptor binding and G protein coupling on discrete regions of the basal ganglia. J. Neurosci. Res. 2005, 82:264-272.
4. Clark R.A., Shoaib M., Hewitt K.N., Stanford S.C., Bate S.T. A comparison of InVivoStat with other statistical software packages for analysis of data generated from animal experiments. J. Psychopharmacol. 2012, 26:1136-1142.
5. Dalton V.S., Long L.E., Weickert C.S., Zavitsanou K. Paranoid schizophrenia is characterized by increased CB1 receptor binding in the dorsolateral prefrontal cortex. Neuropsychopharmacology 2011, 36:1620-1630.
6. De Marchi N., De Petrocellis L., Orlando P., Daniele F., Fezza F., Di Marzo V. Endocannabinoid signalling in the blood of patients with schizophrenia. Lipids Health Dis. 2003, 2:5.
7. 3H]CP-55940 binding in the human central nervous system: regional specific changes in density of cannabinoid-1 receptors associated with schizophrenia and Cannabis use. Neuroscience 2001, 103:9-15.
8. Di Marzo V., Maccarrone M. FAAH and anandamide: is 2-AG really the odd one out?. Trends Pharmacol. Sci. 2008, 29:229-233.
9. Fernandez-Espejo E., Viveros M.P., Nuñez L., Ellenbroek B.A., Rodriguez de Fonseca F. Role of Cannabis and endocannabinoids in the genesis of schizophrenia. Psychopharmacology (Berl.) 2009, 206:531-549.
10. García-Sevilla J.A., Alvaro-Bartolome M., Diez-Alarcia R., Ramos-Miguel A., Puigdemont D., Perez V., Alvarez E., Meana J.J. Reduced platelet G protein-coupled receptor kinase 2 in major depressive disorder: antidepressant treatment-induced upregulation of GRK2 protein discriminates between responder and non-responder patients. Eur. Neuropsychopharmacol. 2010, 20:721-730.
11. Giuffrida A., Parsons L.H., Kerr T.M., Rodríguez de Fonseca F., Navarro M., Piomelli D. Dopamine activation of endogenous cannabinoid signaling in dorsal striatum. Nat. Neurosci. 1999, 2:358-363.
12. Giuffrida A., Leweke F.M., Gerth C.W., Schreiber D., Koethe D., Faulhaber J., Klosterkötter J., Piomelli D. Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms. Neuropsychopharmacology 2004, 29:2108-2114.
13. Insel T.R. Rethinking schizophrenia. Nature 2010, 468:187-193.
14. Katona I., Urban G.M., Wallace M., Ledent C., Jung K.-M., Piomelli D., Mackie K., Freund T.F. Molecular composition of the endocannabinoid system at glutamatergic synapses. J. Neurosci. 2006, 26:5628-5637.
15. Koethe D., Giuffrida A., Schreiber D., Hellmich M., Schultze-Lutter F., Ruhrmann S., Klosterkötter J., Piomelli D., Lewewke F.M. Anandamide elevation in cerebrospinal fluid in initial prodromal states of psychosis. Br. J. Psychiatry 2009, 194:371-372.
16. Lehtonen M., Storvik M., Malinen H., Hyytiä P., Lakso M., Auriola S., Wong G., Callaway J.C. Determination of endocannabinoids in nematodes and human brain tissue by liquid chromatography electrospray ionization tandem mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2011, 879:677-694.
17. Leweke F.M., Giuffrida A., Wurster U., Emrich H.M., Piomelli D. Elevated endogenous cannabinoids in schizophrenia. Neuroreport 1999, 8:1665-1669.
18. Leweke F.M., Piomelli D., Pahlisch F., Muhl D., Gerth C.W., Hoyer C., Klosterkötter J., Hellmich M., Koethe D. Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Transl. Psychiatry 2012, 2:e94. 10.1038/tp.2012.15.
19. Maccarrone M., Rossi S., Bari M., De Chiara V., Fezza F., Musella A., Gasperi V., Prosperetti C., Bernardi G., Finazzi-Agrò A., Cravatt B.F., Centonze D. Anandamide inhibits metabolism and physiological actions of 2-arachidonoylglycerol in the striatum. Nat. Neurosci. 2008, 11:152-159.
20. Melis M., Perra S., Muntoni A.L., Pillolla G., Lutz B., Marsicano G., Di Marzo V., Gessa G.L., Pistis M. Prefrontal cortex stimulation induces 2-arachidonoyl-glycerol mediated suppression of excitation in dopamine neurons. J. Neurosci. 2004, 24:10707-10715.
21. Moghaddam B., Javitt D. From revolution to evolution: the glutamate hypothesis of schizophrenia and its implication for treatment. Neuropsychopharmacology 2012, 37:4-15.
22. Newell K.A., Deng C., Huang X.F. Increased cannabinoid receptor density in the posterior cingulate cortex in schizophrenia. Exp. Brain Res. 2006, 172:556-560.
23. 1 and CB[U+2082]. Pharmacol. Rev. 2010, 62:588-631.
24. Pryor S.R. Is platelet release of 2-arachidonoyl-glycerol a mediator of cognitive deficits? An endocannabinoid theory of schizophrenia and arousal. Med. Hypotheses 2000, 55:494-501.
25. Rajkowska G., Goldman-Rakic P.S. Cytoarchitectonic definition of prefrontal areas in the normal human cortex: I. Remapping of areas 9 and 46 using quantitative criteria. Cereb. Cortex 1995, 5:307-322.
26. Tzavara E.T., Li D.L., Moutsimili L., Bisogno T., Di Marzo V., Phebus L.A., Nomikos G.G., Giros B. Endocannabinoids activate transient receptor potential vanilloid 1 receptor to reduce hyperdopaminergia-related hyperactivity: therapeutic implications. Biol. Psychiatry 2005, 59:508-515.
27. 1 cannabinoid receptors in postmortem frontal cortex of subjects with schizophrenia: effect of antipsychotic treatment. Psychopharmacology (Berl.) 2009, 206:313-324.
28. Vigano D., Guidalia C., Petrosino S., Realini N., Rubino T., Di Marzo V., Parolaro D. Involvement of the endocannabinoid system in phencyclidine-induced cognitive deficits modelling schizophrenia. Int. J. Neuropsychopharmacol. 2009, 12:599-614.
29. 11C]OMAR. Neuroimage 2010, 52:1505-1513.
30. 3H]SR141716A binding to cannabinoid CB1 receptors is increased in the anterior cingulate cortex in schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 2004, 28:355-360.